Compare QUALCOMM, Inc. (QCOM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Repligen Corporation Common Stock — how do they compare? QUALCOMM, Inc. trades at $170.99 (market cap $188.86B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: QUALCOMM, Inc. is far larger — about 17× Repligen Corporation Common Stock's market cap, and QUALCOMM, Inc. pays a 2.08% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold QUALCOMM, Inc. for 87 Days and Repligen Corporation Common Stock for 0 Days on average.
| QCOM | RGEN | |
|---|---|---|
Market Cap | $188.86B | $11.14B |
Volume | 12,280,716 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $251.10 | $194.57 |
52-Week Low | $124.07 | $102.87 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $195.82B | $11.02B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $174.43, down 0.61% today, with a bearish technical signal despite recent AI-driven optimism. The company reported mixed Q2 2026 earnings, missing EPS estimates at $2.21 versus $2.23 expected, but maintains strong profitability with 54.23% gross margins and 21.01% net income margin. Recent news highlights a transformative $60 billion Amazon AI partnership, boosting data center ambitions beyond its core handset business.
QCOM's valuation appears reasonable with a P/E of 20.21, trading below the analyst consensus price target of $204.48. Key opportunities include AI data center growth and automotive expansion, while risks involve smartphone dependency and competitive pressures. Wall Street sentiment is mixed with 43.48% buy ratings, but the stock offers potential upside if AI bets materialize.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
